Beijing Sun-Novo Pharmaceutical Research Co Ltd
SSE:688621
Beijing Sun-Novo Pharmaceutical Research Co Ltd
SSE:688621
Price:
58.78
CNY
0.36%
Market Cap:
¥6.6B
Income Statement
Earnings Waterfall
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Income Statement
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Currency: CNY
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||
| Interest Expense |
1
|
1
|
1
|
0
|
4
|
2
|
5
|
7
|
10
|
11
|
10
|
11
|
12
|
14
|
15
|
16
|
16
|
15
|
0
|
|
| Revenue |
347
N/A
|
369
+6%
|
416
+13%
|
454
+9%
|
494
+9%
|
546
+11%
|
594
+9%
|
648
+9%
|
677
+4%
|
761
+12%
|
813
+7%
|
873
+7%
|
932
+7%
|
952
+2%
|
1 034
+9%
|
1 157
+12%
|
1 078
-7%
|
1 057
-2%
|
1 106
+5%
|
|
| Gross Profit | ||||||||||||||||||||
| Cost of Revenue |
(175)
|
(179)
|
(200)
|
(208)
|
(230)
|
(251)
|
(267)
|
(296)
|
(301)
|
(356)
|
(366)
|
(393)
|
(404)
|
(389)
|
(454)
|
(540)
|
(537)
|
(562)
|
(578)
|
|
| Gross Profit |
172
N/A
|
191
+11%
|
216
+13%
|
246
+14%
|
264
+7%
|
295
+12%
|
327
+11%
|
352
+8%
|
376
+7%
|
405
+8%
|
448
+10%
|
481
+7%
|
528
+10%
|
563
+6%
|
580
+3%
|
617
+6%
|
541
-12%
|
495
-9%
|
528
+7%
|
|
| Operating Income | ||||||||||||||||||||
| Operating Expenses |
(89)
|
(102)
|
(108)
|
(123)
|
(140)
|
(158)
|
(178)
|
(190)
|
(205)
|
(220)
|
(244)
|
(263)
|
(331)
|
(342)
|
(351)
|
(376)
|
(351)
|
(356)
|
(353)
|
|
| Selling, General & Administrative |
(54)
|
(63)
|
(71)
|
(76)
|
(95)
|
(107)
|
(120)
|
(131)
|
(124)
|
(144)
|
(153)
|
(159)
|
(204)
|
(216)
|
(224)
|
(228)
|
(187)
|
(203)
|
(197)
|
|
| Research & Development |
(32)
|
(39)
|
(40)
|
(49)
|
(45)
|
(54)
|
(64)
|
(69)
|
(81)
|
(92)
|
(107)
|
(116)
|
(106)
|
(139)
|
(139)
|
(160)
|
(154)
|
(175)
|
(179)
|
|
| Depreciation & Amortization |
(4)
|
(2)
|
(2)
|
0
|
(5)
|
0
|
0
|
0
|
(16)
|
0
|
0
|
0
|
(29)
|
0
|
0
|
0
|
(28)
|
0
|
0
|
|
| Other Operating Expenses |
1
|
2
|
5
|
4
|
5
|
5
|
6
|
9
|
16
|
16
|
16
|
13
|
8
|
14
|
12
|
12
|
17
|
21
|
23
|
|
| Operating Income |
83
N/A
|
89
+6%
|
108
+22%
|
124
+14%
|
124
N/A
|
137
+11%
|
150
+9%
|
162
+8%
|
170
+5%
|
186
+9%
|
204
+10%
|
218
+7%
|
198
-9%
|
221
+12%
|
228
+3%
|
241
+5%
|
190
-21%
|
139
-27%
|
174
+26%
|
|
| Pre-Tax Income | ||||||||||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
(1)
|
(0)
|
(1)
|
(1)
|
0
|
(1)
|
(1)
|
(2)
|
(4)
|
(4)
|
(4)
|
(5)
|
(6)
|
(8)
|
(12)
|
(12)
|
(16)
|
|
| Non-Reccuring Items |
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
(0)
|
0
|
(1)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
|
| Total Other Income |
(0)
|
(0)
|
(0)
|
0
|
0
|
(0)
|
(0)
|
(1)
|
0
|
(0)
|
(0)
|
(1)
|
(0)
|
(1)
|
(2)
|
(2)
|
(1)
|
(2)
|
(2)
|
|
| Pre-Tax Income |
82
N/A
|
88
+7%
|
107
+21%
|
123
+15%
|
122
-1%
|
136
+11%
|
150
+10%
|
161
+7%
|
169
+5%
|
183
+8%
|
200
+9%
|
214
+7%
|
193
-10%
|
215
+11%
|
220
+2%
|
231
+5%
|
176
-24%
|
125
-29%
|
157
+26%
|
|
| Net Income | ||||||||||||||||||||
| Tax Provision |
(8)
|
(9)
|
(13)
|
(14)
|
(13)
|
(14)
|
(14)
|
(9)
|
(11)
|
(12)
|
(10)
|
(14)
|
(11)
|
(12)
|
(15)
|
(17)
|
(7)
|
3
|
(0)
|
|
| Income from Continuing Operations |
74
|
79
|
94
|
109
|
109
|
122
|
135
|
152
|
158
|
171
|
190
|
200
|
183
|
204
|
205
|
214
|
169
|
128
|
157
|
|
| Income to Minority Interest |
(2)
|
(3)
|
(4)
|
(3)
|
(3)
|
(4)
|
(1)
|
(3)
|
(2)
|
(1)
|
(4)
|
(2)
|
2
|
6
|
10
|
7
|
8
|
7
|
2
|
|
| Net Income (Common) |
73
N/A
|
76
+4%
|
91
+20%
|
107
+18%
|
106
-1%
|
119
+12%
|
134
+13%
|
149
+11%
|
156
+4%
|
170
+9%
|
187
+9%
|
198
+6%
|
185
-7%
|
210
+13%
|
215
+3%
|
221
+3%
|
177
-20%
|
134
-24%
|
159
+18%
|
|
| EPS (Diluted) |
0.65
N/A
|
0.67
+3%
|
1.6
+139%
|
1.26
-21%
|
1.08
-14%
|
1.05
-3%
|
1.19
+13%
|
1.33
+12%
|
1.39
+5%
|
1.52
+9%
|
1.67
+10%
|
1.77
+6%
|
1.65
-7%
|
1.88
+14%
|
1.92
+2%
|
1.98
+3%
|
1.58
-20%
|
1.22
-23%
|
1.43
+17%
|
|
Switch to:
Switch to:
See Also
Discover More
